BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37139982)

  • 1. Muscle loss during cancer therapy is associated with poor outcomes in advanced ovarian cancer.
    Polen-De C; Giri S; Fadadu P; Weaver A; Mcgree ME; Moynagh M; Takahashi N; Jatoi A; Lebrasseur NK; Cliby W; Williams G; Kumar A
    J Natl Cancer Inst Monogr; 2023 May; 2023(61):43-48. PubMed ID: 37139982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
    Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
    J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.
    Shachar SS; Deal AM; Weinberg M; Nyrop KA; Williams GR; Nishijima TF; Benbow JM; Muss HB
    Clin Cancer Res; 2017 Feb; 23(3):658-665. PubMed ID: 27489287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced-stage ovarian cancer.
    Huang CY; Yang YC; Chen TC; Chen JR; Chen YJ; Wu MH; Jan YT; Chang CL; Lee J
    J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):534-546. PubMed ID: 31999069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
    Kim IH; Choi MH; Lee IS; Hong TH; Lee MA
    BMC Cancer; 2021 Jan; 21(1):77. PubMed ID: 33461517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
    Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
    PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of prognostic nutritional index with muscle loss and survival in patients with ovarian cancer treated with primary debulking surgery and chemotherapy.
    Lee J; Weng CS; Chang CL; Hsu WH; Jan YT; Wu KP
    Support Care Cancer; 2023 Apr; 31(5):267. PubMed ID: 37058264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study.
    Järvinen T; Ilonen I; Kauppi J; Salo J; Räsänen J
    World J Surg Oncol; 2018 Feb; 16(1):27. PubMed ID: 29433514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between CT-based body composition assessment and patient outcomes during neoadjuvant chemotherapy for epithelial ovarian cancer.
    Wood N; Morton M; Shah SN; Yao M; Barnard H; Tewari S; Suresh A; Kollikonda S; AlHilli MM
    Gynecol Oncol; 2023 Feb; 169():55-63. PubMed ID: 36508759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.
    Ubachs J; Koole SN; Lahaye M; Fabris C; Bruijs L; Schagen van Leeuwen J; Schreuder HWR; Hermans RH; de Hingh IH; van der Velden J; Arts HJ; van Ham M; van Dam P; Vuylsteke P; Bastings J; Kruitwagen RFPM; Lambrechts S; Olde Damink SWM; Rensen SS; Van Gorp T; Sonke GS; van Driel WJ
    Gynecol Oncol; 2020 Dec; 159(3):706-711. PubMed ID: 33019981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of muscle measurement using the standardized phase of computed tomography in patients with advanced ovarian cancer.
    Huang CY; Sun FJ; Lee J
    Nutrition; 2020 Apr; 72():110642. PubMed ID: 31986319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial.
    Kurk SA; Peeters PHM; Dorresteijn B; de Jong PA; Jourdan M; Creemers GM; Erdkamp FLG; de Jongh FE; Kint PAM; Poppema BJ; Radema SA; Simkens LHJ; Tanis BC; Tjin-A-Ton MLR; Van Der Velden A; Punt CJA; Koopman M; May AM
    Cancer Med; 2020 Feb; 9(3):1033-1043. PubMed ID: 31850687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarcopenia in Advanced Serous Ovarian Cancer.
    Bronger H; Hederich P; Hapfelmeier A; Metz S; Noël PB; Kiechle M; Schmalfeldt B
    Int J Gynecol Cancer; 2017 Feb; 27(2):223-232. PubMed ID: 27870708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer.
    ; Mari A; D'Andrea D; Kimura S; Resch I; Shariat SF; Klatte T
    Urol Int; 2018; 101(2):197-200. PubMed ID: 30089304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients triaged to neoadjuvant chemotherapy have higher rates of sarcopenia: An opportunity for prehabilitation.
    Fadadu PP; Polen-De CL; McGree ME; Weaver AL; Moynagh MR; Takahashi N; Langstraat CL; Cliby WA; Kumar A
    Gynecol Oncol; 2021 Jan; 160(1):40-44. PubMed ID: 33109391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer.
    Kumar A; Moynagh MR; Multinu F; Cliby WA; McGree ME; Weaver AL; Young PM; Bakkum-Gamez JN; Langstraat CL; Dowdy SC; Jatoi A; Mariani A
    Gynecol Oncol; 2016 Aug; 142(2):311-6. PubMed ID: 27235857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma.
    Nakamura N; Hara T; Shibata Y; Matsumoto T; Nakamura H; Ninomiya S; Kito Y; Kitagawa J; Kanemura N; Goto N; Shiraki M; Miyazaki T; Takeuchi T; Shimizu M; Tsurumi H
    Ann Hematol; 2015 Dec; 94(12):2043-53. PubMed ID: 26385388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of multidetector computed tomography quantitative measurements in identifying sarcopenia: a propensity score matched study.
    Zuo YQ; Gao ZH; Wang Z; Liu Q; Yang X; Yin YL; Feng PY
    Skeletal Radiol; 2022 Jun; 51(6):1303-1312. PubMed ID: 34757481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients.
    Kurk S; Peeters P; Stellato R; Dorresteijn B; de Jong P; Jourdan M; Creemers GJ; Erdkamp F; de Jongh F; Kint P; Simkens L; Tanis B; Tjin-A-Ton M; Van Der Velden A; Punt C; Koopman M; May A
    J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):803-813. PubMed ID: 31094083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of sarcopenic obesity and prediction of long-term survival in patients with gastric cancer using preoperative computed tomography and machine learning.
    Kim J; Han SH; Kim HI
    J Surg Oncol; 2021 Dec; 124(8):1347-1355. PubMed ID: 34490899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.